Bibliography
- LLOYD-JONES DM, LARSON MG, BEISER A, LEVY D: Life-time risk of developing coronary heart disease. Lancet (1999) 353:89–92.
- ELY SW, BERNE RM: Protective effects of adenosine in myocardial ischemia. Circulation (1992) 85:893–904.
- MCCORMACK JG, STANLEY WC, WOLFF AA: Ranolazine: a novel metabolic modulator for the treatment of an-gina. Gen. Pharmacol. (1998) 30:639–645.
- TANNER FC, YANG ZY, DUCKERS E, GORDON D, NABEL GJ, NABEL EG: Expression of cyclin-dependent kinase inhibitors in vascular disease. Circ. Res. (1998) 82:396–403.
- WAAGSTEIN F, BRISTOW MR, SWEDBERG K et al.: Benefi-cial effects of metoprolol in idiopathic dilated cardio-myopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet (1993) 342:1441–1446.
- COLUCCI WS, PACKER M, BRISTOW MR et al.: Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation (1996) 94:2800–2806.
- PACKER M, BRISTOW MR, COHN JN et al.: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. New Engl. J. Med. 334:1349-1355.
- HALEEN SJ, CHENG XM: Cardiopulmonary indications for endothelin receptor antagonists: review of recent efficacy trials. Exp. Opin. Invest. Drugs (1997) 6:475–487